Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study on post-transplant cyclophosphamide after haploidentical HSCT
2015-003920-30Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in non-Hodgkin lymphoma (NHL), sponsored by Heidelberg University Hospital. Primary endpoint: 1-year progression-free survival (binary). Started Apr 2016; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2015-003920-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003920-30.